BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38245379)

  • 21. The prognostic and predictive impact of
    Park R; Lopes L; Lee S; Riano I; Saeed A
    Future Oncol; 2021 Nov; 17(31):4221-4231. PubMed ID: 34323124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
    Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-agnostic drug development in dMMR/MSI-H solid tumors.
    Bhamidipati D; Subbiah V
    Trends Cancer; 2023 Oct; 9(10):828-839. PubMed ID: 37517955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
    Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
    J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
    Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
    Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
    Stein MK; Oluoha O; Patel K; VanderWalde A
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34198738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation.
    Chung C
    J Oncol Pharm Pract; 2022 Jun; 28(4):850-869. PubMed ID: 33832365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
    Aleksakhina SN; Ivantsov AO; Imyanitov EN
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs.
    Inanaga S; Igase M; Sakai Y; Hagimori K; Sunahara H; Horikirizono H; Itamoto K; Baba K; Ohsato Y; Mizuno T
    J Vet Intern Med; 2022 Sep; 36(5):1760-1769. PubMed ID: 35959511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.
    Bose CK
    Med Oncol; 2022 Apr; 39(5):67. PubMed ID: 35478274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
    Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J
    Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.
    Nunes L; Aasebø K; Mathot L; Ljungström V; Edqvist PH; Sundström M; Dragomir A; Pfeiffer P; Ameur A; Ponten F; Mezheyeuski A; Sorbye H; Sjöblom T; Glimelius B
    Acta Oncol; 2020 Apr; 59(4):417-426. PubMed ID: 31924107
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic landscape and future direction of metastatic colorectal cancer.
    Bando H; Ohtsu A; Yoshino T
    Nat Rev Gastroenterol Hepatol; 2023 May; 20(5):306-322. PubMed ID: 36670267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
    Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.